SEAAIS 2021 76th Annual Meeting

September 23, 2021 to September 26, 2021

The SEAAIS 2021 meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Southeastern Allergy, Asthma and Immunology Society. The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Examine biologics available for the treatment of asthma and discuss recommendations that can be made choosing a biologic for an asthma patient.
  2. Examine testing methods for metal allergy patients.
  3. Review common dermatologic conditions treated by allergists and identify improved treatment options.
  4. Review other uses for biologics such as treating hives and nasal polyps.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

Course summary
Available credit: 
  • 12.75 AMA PRA Category 1 Credit™
  • 12.75 Attendance
Course opens: 
Course expires: 
Event starts: 
09/23/2021 - 6:45pm CDT
Event ends: 
09/26/2021 - 11:15am CDT

All identified conflicts of interest have been mitigated.

The individuals listed below disclose the following financial relationships:

Michael Wechsler, MD
Consultant:  Genentech, AstraZeneca, GSK, Novartis, Regeneron, Sanofi, Amgen, Boehringer Ingelheim

John Oppenheimer, MD
Consultant:  AstraZeneca, Amgen, GSK, Sanofi
Speaker:  ACCP<ACAAI, Sanofi, GSK

J. Allen Meadows, MD
Consultant:  Aimmune, Teva
Speaker: Regeneron, Pfizer, AstraZeneca, Sanofi, Optinose, Teva
Advisory Board Member: Sanofi

David Khan, MD
Author: UpToDate
Co-Editor:  Elsevier

Niraj Patel, MD
Speaker:  CSL Behring, Takeda, Horizon
Advisory Board Member:  Takeda, Horizon

The following have no relevant financial relationships to disclose:
Anna Nowak-Wegrzyn, MD
Jonathan Spergel, MD, PhD
Tina Hartert, MD
Stokes Peebles, MD

Available Credit

  • 12.75 AMA PRA Category 1 Credit™
  • 12.75 Attendance
Please login or create an account to take this course.